Dr. Larry Zisman

Biography

Dr. Zisman has dedicated his career to developing new treatments for pulmonary hypertension. He spent many years taking care of patients with this disease, and saw the need for better treatments. Calling on his background in molecular biology, he embarked on a quest for new ways to address PAH and other as yet incurable pulmonary diseases via drug discovery and research. His passion to make a difference is the driving force behind Pulmokine. Dr. Zisman founded Pulmokine, Inc. in 2007 as a spin-off of Cytopia, Inc., to develop novel therapeutics for pulmonary arterial hypertension (PAH). While at Cytopia, as VP of cardiovascular therapeutics, he championed the development of its kinase inhibitors for PAH, and he has continued that work at Pulmokine. 

Research Interest

Cardiovascular Diseases